Cytokinetics (CYTK) Reports Positive Results From Phase 2 Clinical Trial of Omecamtiv Mecarbil in Japanese Patients With Heart Failure
Tweet Send to a Friend
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Phase 2 clinical trial of omecamtiv mecarbil in Japanese patients with heart ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE